Know with confidence who will benefit from chemotherapy and who will not1-4
TAILORx results eliminate uncertainty around intermediate scores and show that most patients do not benefit from chemotherapy1,2
IMPROVING OUTCOMES OVERALL
Adjuvant chemotherapy may now be guided with an unprecedented level of evidence and precision using the Oncotype DX test to identify:
- the vast majority of patients with no chemotherapy benefit
- the important minority for whom chemotherapy may be life-saving
TAILORx shows that clinical risk features alone are not sufficient to determine chemotherapy benefit1,2
73%
of patients with high clinical risk* had Recurrence Score results 0-25 and may have been overtreated without the Recurrence Score result**
*High clinical risk: Grade 1, >3 cm; Grade 2, >2 cm; Grade 3, >1 cm.
**Based on the primary analysis of TAILORx study
43%
of patients with Recurrence Score results 26-100 had low clinical risk*** and may have been undertreated without the Recurrence Score result
***Low clinical risk: Grade 1, ≤3 cm; Grade 2, ≤2 cm; Grade 3, ≤1 cm.
The largest randomised adjuvant breast cancer treatment trial ever conducted
TAILORx was independently led by ECOG-ACRIN Cancer Research Group with sponsorship from the National Cancer Institute. Participating cancer research groups included the Alliance for Clinical Trials in Oncology, NCIC-Clinical Trials Group, NRG Oncology, and SWOG.
TAILORX: TRANSFORMING THE TREATMENT OF BREAST CANCER
The TAILORx trial followed over 10,000 women with early breast cancer for an average of 9 years. Over 1,000 trial sites in 6 countries participated.
